Tamuzimod improved clinical, endoscopic, and histologic outcomes compared with placebo in moderately to severely active UC at week 52.
Upadacitinib induction and maintenance therapy were associated with higher rates of normalisation of health-related quality-of-life (HRQoL) than placebo.
Tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis.
Perianal fistulising Crohn’s disease was associated with increased IFN-γ expression and response in fistula tracts and luminal mucosa.
Data from the cirrhosis subpopulation in the ZENITH-CKD trial suggest that the zibotentan and dapagliflozin combination may benefit liver health.
This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form.
Within the confines of a single gut microbiome, we have isolated 63 strains from diverse lineages of Segatella. We performed comparative analyses that exposed differences in cellular morphologies, preferences in polysaccharide utilization, yield of short-chain fatty acids, and antibiotic resistance across isolates.
Cendakimab outperformed placebo in patients with eosinophilic oesophagitis (EoE) across various efficacy endpoints in a phase 3 study.
Tradipitant successfully reduced nausea and vomiting associated with motion sickness in a clinical trial. Both low dose and high doses were well-tolerated.
Fluorescence confocal laser microscopy may allow real-time tissue diagnosis from solid pancreatic lesions, via an endoscopic ultrasound procedure.
Partially hydrolysed guar gum (PHGG) appeared to be efficacious in patients with irritable bowel syndrome-associated chronic constipation.
An accelerated treatment algorithm appeared to benefit patients with large pancreatic WON in terms of length-of-stay in the hospital and major complications.
A study found faecal microbiota transplantation was safe and non-inferior to vancomycin in patients with primary Clostridioides difficile infections.
Etrasimod was associated with favourable outcomes and tolerability in patients with moderately to severely active CD in a phase 2 trial extension.
Key issues were discussed at the UEG Week related to current approaches to diagnostics, treatment and practical takeaways of malabsorption syndromes.
A special congres session took a critical look at common errors in the management of lower gastrointestinal conditions, providing insights for clinical practice.
Hepatobiliary and disease guidelines and updates were discussed during a session on prancreas-related cancer, exocrine insufficiency, cysts, and NASH.
The study design is an open-label, parallel, dose-response randomized controlled trial. Thirty vegetarians were assigned to control (no nori), low-dose (5 g nori, aiming to provide 2.4 µg vitamin B12 per day), or high-dose (8 g nori, aiming to provide 4 µg vitamin B12 per day) groups.
We identify functional changes to microbial pathways including dysregulated nucleic acid, amino acid, and carbohydrate metabolism, as well as disruption of intestinal barrier function. Our findings suggest that clock disruption impinges on microbiota composition and intestinal permeability that may contribute to CRC pathogenesis.
This was a retrospective cohort study of patients with no PD history undergoing upper endoscopy with biopsy between January 2000 and December 2005, with final follow-up assessments completed July 31, 2023. The study was conducted within the Mass General Brigham system, a multicenter network in the greater Boston, Massachusetts, area.